WO2008037045A3 - Composition containing a mixture of antidepressants for treating premature ejaculation. - Google Patents

Composition containing a mixture of antidepressants for treating premature ejaculation. Download PDF

Info

Publication number
WO2008037045A3
WO2008037045A3 PCT/BR2007/000262 BR2007000262W WO2008037045A3 WO 2008037045 A3 WO2008037045 A3 WO 2008037045A3 BR 2007000262 W BR2007000262 W BR 2007000262W WO 2008037045 A3 WO2008037045 A3 WO 2008037045A3
Authority
WO
WIPO (PCT)
Prior art keywords
premature ejaculation
treatment
antidepressant
antidepressants
mixture
Prior art date
Application number
PCT/BR2007/000262
Other languages
French (fr)
Other versions
WO2008037045A2 (en
Inventor
Faria Geraldo Eduardo De
Original Assignee
Medley S A Ind Farmaceutica
Faria Geraldo Eduardo De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medley S A Ind Farmaceutica, Faria Geraldo Eduardo De filed Critical Medley S A Ind Farmaceutica
Priority to EP07815704A priority Critical patent/EP2089022A4/en
Publication of WO2008037045A2 publication Critical patent/WO2008037045A2/en
Publication of WO2008037045A3 publication Critical patent/WO2008037045A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention refers to the combined use of antidepressant agents for the treatment of masculine sexual dysfunction, particularly premature ejaculation, considering that the combinations can comprise a Tricyclic Antidepressant (TCA), a Tetracyclic Antidepressant (TeCA), a Selective Serotonin Reuptake Inhibitor (SSRI), and optionally a Serotonin - Norepinefrine Reuptake Inhibitor (SNRI), in pharmaceutical forms offering bioavailability below the conventional doses used for these antidepressant agents, for the treatment of clinical settings of depression. These combinations allow the treatment of premature ejaculation, increasing the Intravaginal Ejaculation Latency Time for a time above 3 minutes, without the occurrence of adverse side effects.
PCT/BR2007/000262 2006-09-28 2007-09-28 Composition containing a mixture of antidepressants for treating premature ejaculation. WO2008037045A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07815704A EP2089022A4 (en) 2006-09-28 2007-09-28 Composition containing a mixture of antidepressants for treating premature ejaculation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0604425-5 2006-09-28
BRPI0604425 2006-09-28

Publications (2)

Publication Number Publication Date
WO2008037045A2 WO2008037045A2 (en) 2008-04-03
WO2008037045A3 true WO2008037045A3 (en) 2008-05-15

Family

ID=39230554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2007/000262 WO2008037045A2 (en) 2006-09-28 2007-09-28 Composition containing a mixture of antidepressants for treating premature ejaculation.

Country Status (2)

Country Link
EP (1) EP2089022A4 (en)
WO (1) WO2008037045A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0912890A2 (en) * 2008-05-19 2015-10-20 Hyun Uk Seol pharmaceutical composition for the treatment of premature ejaculation
WO2016025541A1 (en) * 2014-08-12 2016-02-18 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
WO2018102233A1 (en) * 2016-11-30 2018-06-07 Wang tian xin Therapeutical methods, formulations and nutraceutical formulations
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922341A (en) * 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
WO2002041883A2 (en) * 2000-11-21 2002-05-30 Vivus, Inc. As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
WO2005004855A1 (en) * 2003-07-11 2005-01-20 Worldwide Pe Patent Holdco Pty Ltd Treatment of premature ejaculation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922341A (en) * 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
WO2002041883A2 (en) * 2000-11-21 2002-05-30 Vivus, Inc. As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
WO2005004855A1 (en) * 2003-07-11 2005-01-20 Worldwide Pe Patent Holdco Pty Ltd Treatment of premature ejaculation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2089022A4 *

Also Published As

Publication number Publication date
EP2089022A4 (en) 2012-12-26
EP2089022A2 (en) 2009-08-19
WO2008037045A2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
WO2004047830A3 (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction
UY28752A1 (en) THERAPEUTIC AGENTS
MY136841A (en) Carbamate-substituted pyrazolopyridines
DE602006021444D1 (en) THERAPY FOR THE TREATMENT OF THE OVERACTIVE BUBBLE
WO2007143607A3 (en) Method of treating atrophic vaginitis
MX2013000001A (en) Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration.
EA200900782A1 (en) COMPOSITIONS AND METHODS INTENDED FOR THE TREATMENT OF MUSCULAR AND CARDIOVASCULAR DISORDERS
ECSP099350A (en) TETRAHYDROCICLOPENTA COMPOUNDS [b] INDOL AS MODULATORS
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
WO2007070779A3 (en) A method to treat premature ejaculation in humans
RU2009120988A (en) APPLICATION OF 3-ALPHA-ANDROSTENEDIOL, OPTIONAL IN COMBINATION WITH PHOSPHODESTERASE 5 INHIBITOR, IN THE TREATMENT OF SEXUAL DYSFUNCTION
WO2007005961A3 (en) Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2007005962A3 (en) Combinations of eszopiclone and an antidepressant
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
HUP0202687A2 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
AR047719A1 (en) PROCEDURE FOR THE TREATMENT OF DEPRESSION AND ANXIETY DISORDERS THROUGH COMBINATION THERAPY THAT INCLUDE A BINDING ALFA-2-DELTA AND A SSRI AND / OR A SNRI
WO2008037045A3 (en) Composition containing a mixture of antidepressants for treating premature ejaculation.
MXPA05013016A (en) Aboxadol for treating depression and other affective disorders.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
HUP0302436A2 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
MXPA04011835A (en) Treatment for depression and anxiety by the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent.
CR7271A (en) NEW MELATONIN-BASED PHARMACEUTICAL FORMULATIONS AND SIMILAR COMPOUNDS FOR USE IN SOUND DISORDERS
BRPI0703656A (en) pharmaceutical composition and method for treating sexual dysfunction, a device containing the same and its use
EP1633695A4 (en) Smooth muscle spasmolytic agents
WO2010028130A3 (en) Antidepressant compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07815704

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007815704

Country of ref document: EP